Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive

Total Page:16

File Type:pdf, Size:1020Kb

Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive Neuropsychopharmacology (2015) 40, 2596–2603 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [11C] Harmine Positron Emission Tomography Study 1,2,3,4 1,2 1,2,3 1,2,3 1,2,3,5 Nathan J Kolla , Brittany Matthews , Alan A Wilson , Sylvain Houle , R Michael Bagby , 4,6 3 1,2 *,1,2,3,4 Paul Links , Alexander I Simpson , Amina Hussain and Jeffrey H Meyer 1Centre for Addiction and Mental Health (CAMH) Research Imaging Centre, Toronto, Ontario, Canada; 2Campbell Family Mental Health Research 3 4 Institute, CAMH, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Institute of Medical 5 6 Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychology, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Western Ontario, Toronto, Ontario, Canada Antisocial personality disorder (ASPD) often presents with highly impulsive, violent behavior, and pathological changes in the orbitofrontal cortex (OFC) and ventral striatum (VS) are implicated. Several compelling reasons support a relationship between low monoamine oxidase-A (MAO-A), an enzyme that regulates neurotransmitters, and ASPD. These include MAO-A knockout models in rodents evidencing impulsive aggression and positron emission tomography (PET) studies of healthy subjects reporting associations between low brain MAO-A levels and greater impulsivity or aggression. However, a fundamental gap in the literature is that it is unknown whether brain 11 MAO-A levels are low in more severe, clinical disorders of impulsivity, such as ASPD. To address this issue, we applied [ C] harmine PET to measure MAO-A total distribution volume (MAO-A VT), an index of MAO-A density, in 18 male ASPD participants and 18 age- and sex-matched controls. OFC and VS MAO-A V were lower in ASPD compared with controls (multivariate analysis of variance T (MANOVA): F = 6.8, P = 0.003; OFC and VS MAO-A V each lower by 19%). Similar effects were observed in other brain regions: 2,33 T = = prefrontal cortex, anterior cingulate cortex, dorsal putamen, thalamus, hippocampus, and midbrain (MANOVA: F7,28 2.7, P 0.029). In = − − ASPD, VS MAO-A VT was consistently negatively correlated with self-report and behavioral measures of impulsivity (r 0.50 to 0.52, all P-valueso0.05). This study is the first to demonstrate lower brain MAO-A levels in ASPD. Our results support an important extension of preclinical models of impulsive aggression into a human disorder marked by pathological aggression and impulsivity. Neuropsychopharmacology (2015) 40, 2596–2603; doi:10.1038/npp.2015.106; published online 29 July 2015 INTRODUCTION investigations in clinically diagnosed individuals with the condition, although brain phenotypes such as low orbito- The vast majority of violent crime is perpetrated by a small frontal cortex (OFC) 5-HT2A receptor binding in impulsive group of males who exhibit conduct-disordered behavior males with ASPD (Meyer et al, 2008; Rylands et al, 2012) and from childhood onward and fulfill diagnostic criteria for increased amphetamine-induced nucleus accumbens dopa- antisocial personality disorder (ASPD) as adults (Moffitt mine release in humans with high impulsive-antisocial et al, 2002). Pathological impulsivity is a core symptom of psychopathic traits (Buckholtz et al, 2010) have been ASPD (Swann et al, 2009) that relates to the aversive reported. However, low brain monoamine oxidase-A behaviors and comorbidities associated with the disorder, (MAO-A), an enzyme localized to outer mitochondrial including violent offending (Zhou et al, 2014) and alcohol membranes that metabolizes amine neurotransmitters dependence (AD) (Rubio et al, 2008). There are very few implicated in aggressive behavior (Bortolato et al, 2008), molecular imaging studies of ASPD and, to the best of our has emerged as a promising molecular target. knowledge, no abnormalities are identified from postmortem Multiple tiers of evidence from preclinical and clinical studies support a strong relationship between low or absent MAO-A and impulsive aggression. First, males with a rare *Correspondence: Dr JH Meyer, Centre for Addiction and Mental Health Research Imaging Centre, 250 College St, Toronto, Ontario point mutation in the eighth exon of the MAO-A gene M5T 1R8, Canada, Tel: +1 416 535 8501, Fax: +1 416 979 4656, leading to complete and selective deficiency of MAO-A E-mail: [email protected] exhibit severely impulsive and aggressive behavior (Brunner Received 30 October 2014; revised 9 March 2015; accepted 10 March et al, 1993). Second, positron emission tomography (PET) 2015; accepted article preview online 17 June 2015 studies of healthy humans that used MAO-A-selective Lower monoamine oxidase-A in impulsive and violent males NJ Kolla et al 2597 radiotracers found inverse relationships between MAO-A also exclusionary. Sixty-seven percent of the ASPD sample binding in several brain regions and self-reported anger, had no lifetime exposure to psychotropic medication: four aggression, and hostility (Alia-Klein et al, 2008; Soliman subjects had brief exposures to psychostimulants as children et al, 2011). Third, targeted knockout of MAO-A in mouse but had not taken psychotropic medication as adults. One embryonic stem cells produces impulsively aggressive adult subject received intermittent treatment with an atypical mice (Cases et al, 1995; Scott et al, 2008). Fourth, antipsychotic to manage acute aggression while previously pharmacological inhibition of MAO-A during murine incarcerated but had not been treated in over 5 years. embryogenesis increases impulsive aggression on pharma- Another subject was taking clonazepam intermittently until cologic challenge in adult mice (Mejia et al, 2002). Fifth, 2 months prior to study enrollment. Nine subjects addition- MAO-A genetic polymorphisms that are associated with ally met criteria for current AD. lower MAO-A transcription in cell lines have been found to interact with childhood adversity to increase the risk of adult Control Subjects violent convictions (Caspi et al, 2002). However, it has never been empirically determined whether brain MAO-A is lower Control subjects consisted of nine males with AD and nine in violent and clinically impulsive populations. To address subjects without AD. ASPD subjects were matched to this critical issue, the principal aim of the study was to controls based on the presence or absence of AD comorbid- measure MAO-A total distribution volume (MAO-A VT), an ity, given the association of AD with global alterations of index of MAO-A level, in the brains of highly impulsive, brain MAO-A VT (Matthews et al, 2014). Therefore, we violent offenders with ASPD. included controls with AD to optimize matching. Control [11C] Harmine is a PET radiotracer ideally suited to subjects without AD were screened with the SCID I and measure MAO-A level, because it is reversible, selective for SCID II by an experienced rater and verified by review with a the MAO-A isoenzyme, and binds with high affinity to the psychiatrist (JHM). These subjects had no history of substrate cavity in the center of the MAO-A enzyme (Son psychiatric illness and had not endorsed conduct disorder et al, 2008). Lower MAO-A levels are associated with lower symptoms as children or youth. Control subjects with AD MAO-A activity in the brain (Saura et al, 1992). were also screened with the SCID I and SCID II, which was We hypothesized that MAO-A VT would be lower in the verified by a psychiatrist (JHM). This subset of controls had OFC and ventral striatum (VS) of ASPD with impulsive no lifetime history of additional psychiatric illness, including violence and that OFC and VS MAO-A VT would vary ASPD. One AD subject had been treated with diazepam for inversely with measures of impulsivity. The OFC and VS alcohol withdrawal 15 years prior to his involvement in the were chosen as the main regions of interest (ROI), because study. None of the other control participants had any they show consistent functional and/or biological abnorm- previous psychotropic medication exposure. Control subjects alities in ASPD and aggressive behavior (Blair, 2004; were age-matched within 4 years to the ASPD participants. Buckholtz et al, 2010; Glenn and Yang, 2012; Meyer et al, Control subjects formed a subset of participants from 2008; Rylands et al, 2012) and are key structures in the neural previously published studies in our laboratory (Matthews circuitry mediating impulsivity (Dalley et al, 2011). et al, 2014; Soliman et al, 2011). None of the study subjects was a current smoker: 38.9% of the ASPD subjects and 33.3% of the control subjects were past smokers (P = 1.0, two-tailed MATERIALS AND METHODS Fisher’s exact test). Non-smoking status was verified in the Participants ASPD and AD control subjects by self-report and breath- alyzer testing for carbon monoxide (MicroSmokerlyzer; Thirty-six males completed the study protocol: 18 partici- Bedfont Scientific, Kent, United Kingdom) and by self- pants with ASPD and 18 control participants without ASPD. report in the healthy control subjects. All subjects provided Each participant provided written consent following expla- negative urine drug screen tests on assessment and PET nation of study procedures. All study components were scanning days. Study subjects
Recommended publications
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
    (19) TZZ ¥__T (11) EP 2 998 314 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2016 Bulletin 2016/12 C07K 7/08 (2006.01) A61K 38/10 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) (21) Application number: 15190713.6 (22) Date of filing: 04.06.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • SHAILUBHAI, Kunwar HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Audubon, PA 19402 (US) RO SE SI SK TR • JACOB, Gary S. New York, NY 10028 (US) (30) Priority: 04.06.2007 US 933194 P (74) Representative: Cooley (UK) LLP (62) Document number(s) of the earlier application(s) in Dashwood accordance with Art. 76 EPC: 69 Old Broad Street 12162903.4 / 2 527 360 London EC2M 1QS (GB) 08770135.5 / 2 170 930 Remarks: (71) Applicant: Synergy Pharmaceuticals Inc. This application was filed on 21-10-2015 as a New York, NY 10170 (US) divisional application to the application mentioned under INID code 62. (54) AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS (57) The invention provides novel guanylate cycla- esterase. The gastrointestinal disorder may be classified se-C agonist peptides and their use in the treatment of as either irritable bowel syndrome, constipation, or ex- human diseases including gastrointestinal disorders, in- cessive acidity etc. The gastrointestinal disease may be flammation or cancer (e.g., a gastrointestinal cancer).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • Befloxatone in the Human Brain, a Selective Radioligand To
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Zanotti-Fregonara et al. EJNMMI Research 2013, 3:78 http://www.ejnmmires.com/content/3/1/78 ORIGINAL RESEARCH Open Access Kinetic analysis of [11C]befloxatone in the human brain, a selective radioligand to image monoamine oxidase A Paolo Zanotti-Fregonara1*, Claire Leroy2,3, Dimitri Roumenov2, Christian Trichard3, Jean-Luc Martinot3 and Michel Bottlaender2,4 Abstract Background: [11C]Befloxatone measures the density of the enzyme monoamine oxidase A (MAO-A) in the brain. MAO-A is responsible for the degradation of different neurotransmitters and is implicated in several neurologic and 11 psychiatric illnesses. This study sought to estimate the distribution volume (VT) values of [ C]befloxatone in humans using an arterial input function. Methods: Seven healthy volunteers were imaged with positron emission tomography (PET) after [11C]befloxatone injection. Kinetic analysis was performed using an arterial input function in association with compartmental modeling and with the Logan plot, multilinear analysis (MA1), and standard spectral analysis (SA) at both the regional and voxel level. Arterialized venous samples were drawn as an alternative and less invasive input function. Results: An unconstrained two-compartment model reliably quantified VT values in large brain regions. A constrained model did not significantly improve VT identifiability. Similar VT results were obtained using SA; however, the Logan plot and MA1 slightly underestimated VT values (about −10%). At the voxel level, SA showed a very small bias (+2%) compared to compartmental modeling, Logan severely underestimated VT values, and voxel-wise images obtained with MA1 were too noisy to be reliably quantified.
    [Show full text]
  • [11C]Harmine for Imaging of MAO-A for Clinical Trials
    Applied Radiation and Isotopes 97 (2015) 182–187 Contents lists available at ScienceDirect Applied Radiation and Isotopes journal homepage: www.elsevier.com/locate/apradiso Parameter evaluation and fully-automated radiosynthesis of [11C]harmine for imaging of MAO-A for clinical trials C. Philippe a, M. Zeilinger a, M. Mitterhauser a, M. Dumanic a, R. Lanzenberger b, M. Hacker a, W. Wadsak a,n a Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria b Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria HIGHLIGHTS Preparation of [11C]harmine on a commercially available synthesizer for the routine application. High reliability: only 4 out of 72 failed syntheses; 5% due to technical problems. High yields: 6.171 GBq overall yield (EOS). High specific activities: 101.32728.2 GBq/mmol. article info abstract Article history: The aim of the present study was the evaluation and automation of the radiosynthesis of [11C]harmine Received 28 October 2014 for clinical trials. The following parameters have been investigated: amount of base, precursor con- Received in revised form centration, solvent, reaction temperature and time. The optimum reaction conditions were determined 4 December 2014 to be 2–3 mg/mL precursor activated with 1 eq. 5 M NaOH in DMSO, 80 °C reaction temperature and Accepted 4 January 2015 2 min reaction time. Under these conditions 6.171 GBq (51.0711% based on [11C]CH I, corrected for Available online 7 January 2015 3 decay) of [11C]harmine (n¼72) were obtained.
    [Show full text]
  • Selegiline Binding to Monoamine Oxidase Enzyme
    Nagy & Kalász RJLBPCS 2017 www.rjlbpcs.com Life Science Informatics Publications Original Research Article DOI - 10.26479/2017.0302.10 SELEGILINE BINDING TO MONOAMINE OXIDASE ENZYME IN THE REAR VIEW MIRROR J Nagy 1, 2, H Kalász 2* 1.Liver Studies Unit and Molecular Biology Division, Veteran Administration Medical Center, San Francisco, CA, USA 2.Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Nagyvárad tér 4, Hungary. ABSTRACT: The oxidation of various endogenous monoamine compounds is catalyzed by MAO [monoamine oxidase enzyme, EC 1.4.3.4], that exist in multiple forms, such as MAO-A and MAO-B. MAO-B catalizes the breakdown of benzylamine and phenylethylamine, while both MAO-A and MAO-B play an essential role in the oxidative elimination of tyramine, triptamine and dopamine. One therapeutic target of MAO enzymes is to reduce their catalysis of the breakdown of dopamine. Knoll and Magyar discovered that MAO-B is highly sensitive to selegiline [[-]-deprenyl], which is its irreversible inhibitor. Singer, Nagy and Salach identified the amino acid sequence of this peptide and also the active site of flavin-peptide complex, which is the binding site of MAO inhibitors. Flavin-peptide unit of placental MAO was isolated using proteolytic digestion, treatment with trichloroacetic acid, followed by a three-step chromatographic separation using Florisil, Bio-Gel P-2 and Sephadex G-15. MAO binding sites were located using x-ray diffraction, and they were identified using translational neuroimaging; positron emission tomography studies of monoamine oxidase + [11C]-compounds and tracing ligand-binding active sites of irreversible inhibitors: clorgyline, selegiline and their derivatives.
    [Show full text]
  • Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
    Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Related Titles Smith, D. A., Allerton, C., Kalgutkar, A. S., Curry, S. H., Whelpton, R. van de Waterbeemd, H., Walker, D. K. Drug Disposition and Pharmacokinetics and Metabolism Pharmacokinetics in Drug Design From Principles to Applications 2012 2011 ISBN: 978-3-527-32954-0 ISBN: 978-0-470-68446-7 Gad, S. C. (ed.) Rankovic, Z., Morphy, R. Development of Therapeutic Lead Generation Approaches Agents Handbook in Drug Discovery 2012 2010 ISBN: 978-0-471-21385-7 ISBN: 978-0-470-25761-6 Tsaioun, K., Kates, S. A. (eds.) Han, C., Davis, C. B., Wang, B. (eds.) ADMET for Medicinal Chemists Evaluation of Drug Candidates A Practical Guide for Preclinical Development 2011 Pharmacokinetics, Metabolism, ISBN: 978-0-470-48407-4 Pharmaceutics, and Toxicology 2010 ISBN: 978-0-470-04491-9 Sotriffer, C. (ed.) Virtual Screening Principles, Challenges, and Practical Faller, B., Urban, L. (eds.) Guidelines Hit and Lead Profiling 2011 Identification and Optimization ISBN: 978-3-527-32636-5 of Drug-like Molecules 2009 ISBN: 978-3-527-32331-9 Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Pharmacokinetic Properties of Functional Groups and Organic Compounds The Author All books published by Wiley-VCH are carefully produced. Nevertheless, authors, Dr. Florencio Zaragoza D¨orwald editors, and publisher do not warrant the Lonza AG information contained in these books, Rottenstrasse 6 including this book, to be free of errors. 3930 Visp Readers are advised to keep in mind that Switzerland statements, data, illustrations, procedural details or other items may inadvertently be Cover illustration: inaccurate.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Approches Pharmacologique Et Génétique in Vivo Chez La Souris Thanh Hai Nguyen
    Cibles sérotoninergiques et non sérotoninergiques des ISRS : approches pharmacologique et génétique in vivo chez la souris Thanh Hai Nguyen To cite this version: Thanh Hai Nguyen. Cibles sérotoninergiques et non sérotoninergiques des ISRS : approches pharma- cologique et génétique in vivo chez la souris. Médecine humaine et pathologie. Université Paris Sud - Paris XI, 2011. Français. NNT : 2011PA114833. tel-00663312 HAL Id: tel-00663312 https://tel.archives-ouvertes.fr/tel-00663312 Submitted on 26 Jan 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITÉ PARIS-SUD 11 ECOLE DOCTORALE : INNOVATION THÉRAPEUTIQUE : DU FONDAMENTAL A L’APPLIQUÉ PÔLE : PHARMACOLOGIE ET TOXICOLOGIE DISCIPLINE : Neuropharmacologie ANNÉE 2010 - 2011 SÉRIE DOCTORAT N° THÈSE DE DOCTORAT Soutenue le 30 novembre 2011 Par Thanh Hai NGUYEN Cibles sérotoninergiques et non sérotoninergiques des ISRS : Approches Pharmacologique et Génétique in vivo chez la souris Directeur de thèse : Pr Alain GARDIER Co-directeur de thèse : Dr Bruno GUIARD Rapporteurs : Pr Michel BOULOUARD
    [Show full text]
  • Potent Selective Inhibition of Monoamine Oxidase a By
    J. Microbiol. Biotechnol. (2017), 27(2), 316–320 https://doi.org/10.4014/jmb.1610.10053 Research Article Review jmb Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from Alternaria brassicae Hyun Woo Lee1, Yeon Ji Kim2, Sang-Jip Nam2, and Hoon Kim1* 1Department of Pharmacy and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea 2Department of Chemistry and Nano Science, Ewha Womans University, Seoul 03760, Republic of Korea Received: October 21, 2016 Revised: October 28, 2016 Alternariol monomethyl ether (AME), a dibenzopyrone derivative, was isolated from Accepted: November 4, 2016 Alternaria brassicae along with altertoxin II (ATX-II). The compounds were tested for the inhibitory activity of monoamine oxidase (MAO), which catalyzes neurotransmitting monoamines. AME was found to be a highly potent and selective inhibitor of human MAO-A First published online with an IC50 value of 1.71 µM; however, it was found to be ineffective for MAO-B inhibition. November 14, 2016 ATX-II was not effective for the inhibition of either MAO-A or MAO-B. The inhibition of *Corresponding author MAO-A using AME was apparently instantaneous. MAO-A activity was almost completely Phone: +82-61-750-3751; recovered after the dilution of the inhibited enzyme with an excess amount of AME, Fax: +82-61-750-3708; suggesting AME is a reversible inhibitor. AME showed mixed inhibition for MAO-A in E-mail: [email protected] Lineweaver-Burk plots with a Ki value of 0.34 µM. The findings of this study suggest that microbial metabolites and dibenzopyrone could be potent MAO inhibitors.
    [Show full text]
  • Contributions of Tm5, Ecl3 and Tm6 of Human Bcrp to Its Oligomerization Activities and Transport Functions
    CONTRIBUTIONS OF TM5, ECL3 AND TM6 OF HUMAN BCRP TO ITS OLIGOMERIZATION ACTIVITIES AND TRANSPORT FUNCTIONS Wei Mo Submitted to the faculty of the University Graduate School in partial fulfillment of the requirements for the degree Doctor of Philosophy in the Department of Pharmacology and Toxicology, Indiana University August 2011 Accepted by the Faculty of Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Ahmad R. Safa, Ph.D., Co-Chair Jian-Ting Zhang, Ph.D., Co-Chair Doctoral Committee Kai-Ming Chou, Ph.D. June 28, 2011 Barbara A. Hocevar, Ph.D. Martin L. Smith, Ph.D. ii Dedicated to my family, for their endless love, inspiration and support that has guided me throughout my life. To my dearest, Junying Mo Yu Chen Qian Mo Tao Qin Hee Jung Jung Ying Qin iii Acknowledgements I would like to express my gratitude first to my mentor, Dr. Jian-Ting Zhang, for his patience and encouragement throughout all these years of my study and work here. I also sincerely appreciate the support and guidance by other members of my dissertation committee, Dr. Ahmad R. Safa, Dr. Kai-Ming Chou, Dr. Barbara A. Hocevar and Dr. Martin L. Smith. I have furthermore to thank all the members I have worked with in Dr. Zhang’s laboratory for their help and valuable hints. I also want to thank our Department of Pharmacology and Toxicology, for recruiting me into this wonderful family with all the helpful faculties, staffs, students and for providing an extraordinary research environment. This work was supported in part by the Department of Defense Predoctoral Traineeship Award.
    [Show full text]